Logo Logo Logo Logo Logo
  • Home
  • Company
    • Company Focus
    • Leadership Team
    • Scientific Advisory Board
    • Calypso Biotech Operations
    • Board of Directors
  • Science
  • Pipeline
  • Newsroom
  • Contact
  • Careers
  • Home
  • Company
    • Company Focus
    • Leadership Team
    • Scientific Advisory Board
    • Calypso Biotech Operations
    • Board of Directors
  • Science
  • Pipeline
  • Newsroom
  • Contact
  • Careers

16 November 2020: Calypso Biotech announces successful dosing of first Phase 1 cohort with anti-Interleukin-15 (IL-15) monoclonal antibody CALY-002 for the treatment of Autoimmune Diseases

Posted at h in Press release by calypsobiotech

 

Click to see full press release



© Calypso Biotech 2018 – Legal disclaimer